News & Events about Vir Biotechnology Inc.
Vir Biotechnology, Inc. (NASDAQ:VIR Get Rating) has been given a consensus rating of Moderate Buy by the eight analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating...
Vir Biotechnology, Inc. (NASDAQ:VIR Get Rating) has been assigned an average recommendation of Moderate Buy from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy ...
Vir Biotechnology, Inc. (NASDAQ:VIR Get Rating) CTO Ann M. Hanly sold 2,627 shares of the firms stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $22.77, for a total transaction of $59,816.79. Following the transaction, the chief technology ...
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results PR Newswire DURHAM, N.C. and BEIJING, March 24, 2023 Company maintains priority focus on clinical programs to develop a...
Globe Newswire
3 months ago
Final draft guidance based on cost effectiveness evaluation of sotrovimabSAN FRANCISCO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the UKs National Institute for Health and Care Excellence (NICE) provided positive final draft guidance recommending ...